Even with the most advanced therapies, patients with glioblastomas—an aggressive brain tumor—typically survive less than two years after diagnosis. Attempts to treat this cancer with the latest immunotherapies have so far been unsuccessful, likely because glioblastoma cells have few or no natural targets for the immune system.
In a cell-based study, scientists at Washington University School of Medicine in St. Louis have caused glioblastoma cells to present targets for the immune system, potentially making them visible to immune cells and susceptible to immunotherapies. The strategy involves a combination of two drugs, both already approved by the FDA to treat different types of cancer.
The study is published online in the journal Nature Genetics.
Researchers at WashU Medicine have found a potential way to make glioblastoma cells susceptible to various types of immunotherapy. The strategy, which they demonstrated in cells in the lab, forces brain cancer cells to display targets for the immune system. Glioblastoma is one of the most aggressive forms of cancer, as shown in these brain scans of a patient with glioblastoma at initial diagnosis on the left and the same patient with a recurrent tumor on the right.
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn
About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn
About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
TeaserThe expansion of genetic testing for amyotrophic lateral sclerosis (ALS) will lead to a significant increase in clinic visits to specialized ALS centers over the next ten years. A…
Potsdam (LabNews Media LLC) – Researchers at the Fraunhofer Institute for Applied Polymer Research IAP have developed a process for encapsulating adhesives in microcapsules, which only then…
Shanghai (LabNews Media LLC) – China's regulatory authority NMPA has approved Satri-cel (CT041, Kaileimei®), the world's first CAR T-cell therapy for the treatment of a solid tumor.…
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
